IBDEI10Y ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,17047,0)
 ;;=I69.943^^88^857^33
 ;;^UTILITY(U,$J,358.3,17047,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17047,1,3,0)
 ;;=3^Cerebrovascular Disease,Monoplegia,Rt Nondominant Side
 ;;^UTILITY(U,$J,358.3,17047,1,4,0)
 ;;=4^I69.943
 ;;^UTILITY(U,$J,358.3,17047,2)
 ;;=^5133584
 ;;^UTILITY(U,$J,358.3,17048,0)
 ;;=I69.931^^88^857^34
 ;;^UTILITY(U,$J,358.3,17048,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17048,1,3,0)
 ;;=3^Cerebrovascular Disease,Monoplegia,Rt Upper Dominant Side
 ;;^UTILITY(U,$J,358.3,17048,1,4,0)
 ;;=4^I69.931
 ;;^UTILITY(U,$J,358.3,17048,2)
 ;;=^5007558
 ;;^UTILITY(U,$J,358.3,17049,0)
 ;;=I69.933^^88^857^35
 ;;^UTILITY(U,$J,358.3,17049,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17049,1,3,0)
 ;;=3^Cerebrovascular Disease,Monoplegia,Rt Upper Nondominant Side
 ;;^UTILITY(U,$J,358.3,17049,1,4,0)
 ;;=4^I69.933
 ;;^UTILITY(U,$J,358.3,17049,2)
 ;;=^5007559
 ;;^UTILITY(U,$J,358.3,17050,0)
 ;;=I69.998^^88^857^42
 ;;^UTILITY(U,$J,358.3,17050,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17050,1,3,0)
 ;;=3^Cerebrovascular Disease,Sequelae,Unspec
 ;;^UTILITY(U,$J,358.3,17050,1,4,0)
 ;;=4^I69.998
 ;;^UTILITY(U,$J,358.3,17050,2)
 ;;=^5007572
 ;;^UTILITY(U,$J,358.3,17051,0)
 ;;=I69.928^^88^857^43
 ;;^UTILITY(U,$J,358.3,17051,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17051,1,3,0)
 ;;=3^Cerebrovascular Disease,Speech/Language Deficits,Unspec
 ;;^UTILITY(U,$J,358.3,17051,1,4,0)
 ;;=4^I69.928
 ;;^UTILITY(U,$J,358.3,17051,2)
 ;;=^5007557
 ;;^UTILITY(U,$J,358.3,17052,0)
 ;;=I69.965^^88^857^37
 ;;^UTILITY(U,$J,358.3,17052,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17052,1,3,0)
 ;;=3^Cerebrovascular Disease,Paralytic Syndrome,Bilateral,Unspec
 ;;^UTILITY(U,$J,358.3,17052,1,4,0)
 ;;=4^I69.965
 ;;^UTILITY(U,$J,358.3,17052,2)
 ;;=^5007566
 ;;^UTILITY(U,$J,358.3,17053,0)
 ;;=I69.962^^88^857^38
 ;;^UTILITY(U,$J,358.3,17053,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17053,1,3,0)
 ;;=3^Cerebrovascular Disease,Paralytic Syndrome,Lt Dominant Side
 ;;^UTILITY(U,$J,358.3,17053,1,4,0)
 ;;=4^I69.962
 ;;^UTILITY(U,$J,358.3,17053,2)
 ;;=^5133588
 ;;^UTILITY(U,$J,358.3,17054,0)
 ;;=I69.964^^88^857^39
 ;;^UTILITY(U,$J,358.3,17054,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17054,1,3,0)
 ;;=3^Cerebrovascular Disease,Paralytic Syndrome,Lt Nondominant Side
 ;;^UTILITY(U,$J,358.3,17054,1,4,0)
 ;;=4^I69.964
 ;;^UTILITY(U,$J,358.3,17054,2)
 ;;=^5133589
 ;;^UTILITY(U,$J,358.3,17055,0)
 ;;=I69.961^^88^857^40
 ;;^UTILITY(U,$J,358.3,17055,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17055,1,3,0)
 ;;=3^Cerebrovascular Disease,Paralytic Syndrome,Rt Dominant Side
 ;;^UTILITY(U,$J,358.3,17055,1,4,0)
 ;;=4^I69.961
 ;;^UTILITY(U,$J,358.3,17055,2)
 ;;=^5007564
 ;;^UTILITY(U,$J,358.3,17056,0)
 ;;=I69.963^^88^857^41
 ;;^UTILITY(U,$J,358.3,17056,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17056,1,3,0)
 ;;=3^Cerebrovascular Disease,Paralytic Syndrome,Rt Nondominant Side
 ;;^UTILITY(U,$J,358.3,17056,1,4,0)
 ;;=4^I69.963
 ;;^UTILITY(U,$J,358.3,17056,2)
 ;;=^5007565
 ;;^UTILITY(U,$J,358.3,17057,0)
 ;;=G90.50^^88^857^44
 ;;^UTILITY(U,$J,358.3,17057,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17057,1,3,0)
 ;;=3^Complex Regional Pain Syndrome I,Unspec
 ;;^UTILITY(U,$J,358.3,17057,1,4,0)
 ;;=4^G90.50
 ;;^UTILITY(U,$J,358.3,17057,2)
 ;;=^5004163
 ;;^UTILITY(U,$J,358.3,17058,0)
 ;;=R56.9^^88^857^45
 ;;^UTILITY(U,$J,358.3,17058,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17058,1,3,0)
 ;;=3^Convulsions,Unspec
 ;;^UTILITY(U,$J,358.3,17058,1,4,0)
 ;;=4^R56.9
 ;;^UTILITY(U,$J,358.3,17058,2)
 ;;=^5019524
